---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-21-300558"
form_type: "8-K"
ticker: "CGEM"
cik: "0001789972"
company_name: "Cullinan Therapeutics, Inc."
filed_at: "2021-10-18T23:59:59+00:00"
generated_at: "2026-06-28T20:21:06.190605+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Cullinan Oncology CEO Owen Hughes departs; Nadim Ahmed appointed as new President and CEO

## Summary
- CEO Owen Hughes departs Oct 18, 2021; gets 12 months base salary, pro-rata bonus of $216,507, and accelerated vesting.
- Nadim Ahmed appointed CEO, President, and Board member effective Oct 18; previously President of Hematology at BMS.
- Ahmed receives $600k base salary, $625k sign-on bonus, 2.71M stock options, and performance RSUs.
- Hughes will serve as Strategic Advisor for up to 12 months; noncompetition and nondisclosure covenants apply.
- Company reaffirms Pearl update expected in Q4 2021; no change to pipeline plans.

## SEC filing metadata
- accession: 0001193125-21-300558
- form_type: 8-K
- ticker: CGEM
- cik: 0001789972
- company_name: Cullinan Therapeutics, Inc.
- filed_at: 2021-10-18T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1789972/000119312521300558/0001193125-21-300558-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1789972/000119312521300558/d66778d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-21-300558
- JSON: https://secwatch.observer/filing/0001193125-21-300558.json
- Plain text: https://secwatch.observer/filing/0001193125-21-300558.txt

## Key facts
- Executive change
  Owen Hughes departed as President and Chief Executive Officer at Cullinan Therapeutics, Inc..
  - Action: departed
  - Role: President and Chief Executive Officer
  source text: Mr. Hughes’ last date of employment with the Company as its President and Chief Executive Officer is October 18, 2021
  evidence_url: https://www.sec.gov/Archives/edgar/data/1789972/000119312521300558/0001193125-21-300558-index.htm
- Executive change
  Nadim Ahmed was appointed as Class III Director at Cullinan Therapeutics, Inc..
  - Action: appointed
  - Role: Class III Director
  source text: the Board appointed Mr. Ahmed as a Class III director of the Company, effective as of October 18, 2021
  evidence_url: https://www.sec.gov/Archives/edgar/data/1789972/000119312521300558/0001193125-21-300558-index.htm
- Executive change
  Nadim Ahmed was appointed as President and Chief Executive Officer at Cullinan Therapeutics, Inc..
  - Action: appointed
  - Role: President and Chief Executive Officer
  source text: the Board appointed Nadim Ahmed as President and Chief Executive Officer of the Company, effective as of October 18, 2021
  evidence_url: https://www.sec.gov/Archives/edgar/data/1789972/000119312521300558/0001193125-21-300558-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.